Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Diatrizoate meglumine is an iodinated, water-soluble radiopaque contrast agent used primarily to enhance imaging in diagnostic procedures such as retrograde cystourethrography, gastrointestinal studies, angiography, and urography. It works by increasing the contrast of internal body structures on radiographic images due to its high iodine content, which absorbs X-rays. This agent is administered intravenously or via other routes depending on the procedure and is indicated for use under medical supervision[1][2][3][5]. Its primary mechanism of action is physical—providing radiopacity rather than acting through a biochemical target.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on diatrizoate meglumine.